+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center

Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center

Plos one 12(10): E0185850

In this study, we aimed to examine the clinical value of the pleural effusion (PE) biomarkers, soluble mesothelin-related peptide (SMRP), cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA), and the utility of combining chest computed tomography (CT) findings with these biomarkers, in diagnosing malignant pleural mesothelioma (MPM). We conducted a retrospective cohort study in a single center. Consecutive patients with undiagnosed pleural effusions who underwent PE analysis between September 2014 and August 2016 were reviewed. This study included 240 patients (32 with MPM and 208 non-MPM). SMRP and the CYFRA 21-1/CEA ratio had a sensitivity and specificity for diagnosing MPM of 56.3% and 86.5%, and 87.5% and 74.0%, respectively. Using receiver operating characteristics (ROC) curve analysis of the ability of these markers to distinguish MPM from all other PE causes, the area under the ROC curve (AUC) for SMRP and the CYFRA 21-1/CEA ratio was 0.804 and 0.874, respectively. The sensitivity and specificity of SMRP combined with the CYFRA 21-1/CEA ratio were 93.8% and 64.9%, respectively. The sensitivity of the combination of SMRP, the CYFRA 21-1/CEA ratio, and the presence of Leung's criteria (a chest CT finding that is suggestive of malignant pleural disease) was 93.8%. In conclusion, the combined PE biomarkers had a high sensitivity for diagnosing MPM, although the addition of chest CT findings did not improve the sensitivity of SMRP combined with the CYFRA 21-1/CEA ratio. Combination of these biomarkers helped to rule out MPM effectively among patients at high risk of suffering MPM and would be valuable especially for old frail patients who have difficulty in undergoing invasive procedures such as thoracoscopy.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 060101161

Download citation: RISBibTeXText

PMID: 28968445

DOI: 10.1371/journal.pone.0185850

Related references

Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy. European Radiology 29(7): 3696-3704, 2019

Pleural irregularities and mediastinal pleural involvement in early stages of malignant pleural mesothelioma and benign asbestos pleural effusion. European Journal of Radiology 85(9): 1594-1600, 2016

Computed tomography findings of malignant pleural mesothelioma. Nihon Kyobu Shikkan Gakkai Zasshi 32(4): 309-314, 1994

Discriminating Tuberculous Pleural Effusion from Malignant Pleural Effusion Based on Routine Pleural Fluid Biomarkers, Using Mathematical Methods. Tanaffos 16(2): 157-165, 2017

Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?. Respiration; International Review of Thoracic Diseases 89(6): 558-564, 2015

Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: assessment with positron emission tomography-computed tomography. Investigative Radiology 40(4): 204-209, 2005

Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. European Journal of Radiology 41(1): 1-9, 2002

Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis. Plos one 11(11): E0167186, 2016

Computed tomography findings in 66 patients with malignant pleural mesothelioma due to environmental exposure to asbestos. Clinical Imaging 30(3): 177-180, 2006

Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 129(2): 362-368, 2006

49P Accuracy of pleural fluid cytology in patients with malignant pleural effusion from non-small-cell lung cancer, pulmonary metastases and pleural mesothelioma. A case-control study. Journal of Thoracic Oncology 11(4 Suppl.): S75-S75, 2016

Clinical value of tumor supplied group of factor combined with CEA in diagnosing tuberculosis pleural effusion and malignant pleural effusion. Hunan Yi Ke Da Xue Xue Bao 28(6): 608-610, 2003

Prophylactic radiotherapy in a single fraction of 10Gy at intervention pleural site in patient with malignant pleural mesothelioma: A retrospective monocentric cohort study. Cancer Radiotherapie 21(8): 774-783, 2017

Clinical value of vascular endothelial growth factor combined with interferon-gamma in diagnosing malignant pleural effusion and tuberculous pleural effusion. Journal of Huazhong University of Science and Technology. Medical Sciences 27(5): 495-497, 2007

Comparison of cytology, chest computed and positron emission tomography findings in malignant pleural effusion from lung cancer. Journal of Thoracic Disease 10(12): 6903-6911, 2018